Publication date: Jan 01, 2025
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. According to GlobalData, Phase III drugs for Pulmonary Tuberculosis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. It is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients It acts by targeting bacterial cell wall. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is under development for the treatment of pulmonary multidrug-resistant tuberculosis GlobalData’s report assesses how Delamanid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Delamanid is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Pulmonary Tuberculosis.
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Pirenzepine |
disease | MESH | PANIC |
disease | IDO | object |
disease | IDO | site |
pathway | KEGG | Tuberculosis |
disease | MESH | tuberculosis |
drug | DRUGBANK | Coenzyme M |
disease | MESH | Pulmonary Tuberculosis |
drug | DRUGBANK | Delamanid |